KTN's online platform helps you to make the connections you need

 

The Knowledge Transfer Network (KTN) has refreshed its online platform to intelligently connect you to relevant events, funding, thought pieces and specialist staff to help your business innovate and grow.

You can discover content using your area of interest, from Defence Security to transport; from space to health – all major UK economic sectors are covered. Once you have selected your interests, using our intelligent tagging system, we will then display rich and relevant content related to your area, often from surprising sources.

An example might be new satellite technology from the space sector that is applicable in the agri-food sector. KTN-UK.co.uk will help you form these unusual and valuable connections.

All content on the platform has been carefully curated by our team of innovation specialists – not by an automated algorithm – so you can be confident that KTN is connecting you to the most relevant cutting-edge information.

 

The move also marks a closer alignment with our main funder, Innovate UK , with the website branding making a clear visual link. Knowledge Transfer Network is Innovate UK's innovation network partner, and also works with other funders to provide innovation networking services and fulfil our mission to drive UK growth.

We link new ideas and opportunities with expertise, markets and finance through our network of businesses, universities, funders and investors. From agri-food to autonomous systems and from energy to design, KTN combines expertise in all sectors with the ability to cross boundaries. Connecting with KTN can lead to potential partners, horizon-expanding events and innovation insights relevant to your needs.

Visit our people pages to connect directly with expertise in your sector.

Visit the KTN refreshed online platfom here

Entries with tag oncology .

MedImmune and Regeneron Enter into Licensing Agreement for the Development of Antibody Drug Conjugates to Treat Cancer

MedImmune, the global biologics research and development arm of AstraZeneca and Regeneron Pharmaceuticals, Inc., today announced that they have entered into a licensing agreement under which Regeneron will use MedImmune’s pyrrolobenzodiazepine (PBD)-based warhead and linker technology to produce antibody-drug conjugates (ADCs) as potential cancer treatments. Regeneron will have exclusive...
Read More About MedImmune and Regeneron Enter into Licensing Agreement for the Development of Antibody Drug Conjugates to Treat Cancer »

Economic Evaluation for Oncology

This training day focusses on the development of economic models specifically in the area of oncology. The sessions will include overviews of the most common methods for modelling treatments for cancer, and will pay particular attention to the areas that prove most challenging in HTA, including survival curve analysis, data extrapolation, quality of life modelling (including adverse events),...
Read More About Economic Evaluation for Oncology »
Showing 2 results.